Literature DB >> 34344199

Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC.

Jessica Freydman, Lynnette Henshaw, Jasmine V Patel, Claire E Smith, Peter C Everett.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34344199     DOI: 10.1177/10600280211036909

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


× No keyword cloud information.
  1 in total

Review 1.  Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

Authors:  Elisa Bertoli; Elisa De Carlo; Alessandro Del Conte; Brigida Stanzione; Alberto Revelant; Kelly Fassetta; Michele Spina; Alessandra Bearz
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.